In vitro studies and clinical experience have suggested that @entity1 with @entity902 - @entity43 exhibit cross-resistance to radiation. Salvage with radiation in these @entity1 is rare. However, radiation is often utilized to palliate symptoms caused by these chemotherapy-resistant @entity5 . Forty-seven @entity1 with @entity902 - @entity43 were referred for palliative radiation and 33 (70%) were evaluable for response. One to four regimens of @entity902 -based chemotherapy (median 2.7) were given to each @entity1 prior to radiation therapy. Of the 33 evaluable @entity1 , 23 (69.7%) had a complete resolution of symptoms after radiation, 8 (24%) had a partial resolution, and 2 were unassessable because of unrelated medical complications. The median duration of response was 11 months (range 1-86) and closely approximated their survival. Thirteen of 33 @entity1 (39%) obtained relief of symptoms for greater than 12 months, with 10 of 33 (30%) having symptoms controlled for 6 to 12 months. In only 10 @entity1 (30%) was the duration of palliation less than or equal to 6 months. Four @entity1 required reirradiation to the same area for recurrence of their symptom. External-beam radiation therapy can provide effective and durable palliation of symptoms in @entity902 - @entity43 @entity1 .

Palliative benefit of external-beam radiation in the management of @entity902 XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity43 :: ('MESH:D010051', 'Disease') :: ['refractory epithelial ovarian carcinoma'] @entity902 :: ('MESH:D010984', 'Chemical') :: ['platinum'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumors']
@entity43 :: (MESH:D010051,Disease) :: ['refractory epithelial ovarian carcinoma']
